143 related articles for article (PubMed ID: 34693877)
21. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
22. Identification of new Hsp90 inhibitors by structure-based virtual screening.
Hong TJ; Park H; Kim YJ; Jeong JH; Hahn JS
Bioorg Med Chem Lett; 2009 Aug; 19(16):4839-42. PubMed ID: 19560353
[TBL] [Abstract][Full Text] [Related]
23. Theaflavin binds to a druggable pocket of TMEM16A channel and inhibits lung adenocarcinoma cell viability.
Shi S; Ma B; Sun F; Qu C; An H
J Biol Chem; 2021 Sep; 297(3):101016. PubMed ID: 34329684
[TBL] [Abstract][Full Text] [Related]
24. Rational Design of Allosteric and Selective Inhibitors of the Molecular Chaperone TRAP1.
Sanchez-Martin C; Moroni E; Ferraro M; Laquatra C; Cannino G; Masgras I; Negro A; Quadrelli P; Rasola A; Colombo G
Cell Rep; 2020 Apr; 31(3):107531. PubMed ID: 32320652
[TBL] [Abstract][Full Text] [Related]
25. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
26. Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years.
Magwenyane AM; Ugbaja SC; Amoako DG; Somboro AM; Khan RB; Kumalo HM
Comput Math Methods Med; 2022; 2022():2147763. PubMed ID: 35685897
[TBL] [Abstract][Full Text] [Related]
27. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
28. Deciphering the Inhibition Mechanism of under Trial Hsp90 Inhibitors and Their Analogues: A Comparative Molecular Dynamics Simulation.
Nazar A; Abbas G; Azam SS
J Chem Inf Model; 2020 Aug; 60(8):3812-3830. PubMed ID: 32659088
[TBL] [Abstract][Full Text] [Related]
29. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
30. Heat shock protein 90 inhibitors as therapeutic agents.
Gomez-Monterrey I; Sala M; Musella S; Campiglia P
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
[TBL] [Abstract][Full Text] [Related]
31. Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain.
Kim HH; Hyun JS; Choi J; Choi KE; Jee JG; Park SJ
Sci Rep; 2018 Jan; 8(1):368. PubMed ID: 29321504
[TBL] [Abstract][Full Text] [Related]
32. Binding of natural and synthetic inhibitors to human heat shock protein 90 and their clinical application.
Petrikaitė V; Matulis D
Medicina (Kaunas); 2011; 47(8):413-20. PubMed ID: 22123555
[TBL] [Abstract][Full Text] [Related]
33. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
34. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors.
Kadasi S; Costa TEMM; Arukala N; Toshakani M; Duggineti C; Thota S; Dutta Gupta S; Raj S; Penido C; Henriques MG; Raghavendra NM
Med Chem; 2018; 14(1):44-52. PubMed ID: 28641528
[TBL] [Abstract][Full Text] [Related]
35. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.
Casale E; Amboldi N; Brasca MG; Caronni D; Colombo N; Dalvit C; Felder ER; Fogliatto G; Galvani A; Isacchi A; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Casuscelli F
Bioorg Med Chem; 2014 Aug; 22(15):4135-50. PubMed ID: 24980703
[TBL] [Abstract][Full Text] [Related]
36. The in silico identification of potent anti-cancer agents by targeting the ATP binding site of the N-domain of HSP90.
Sepehri B; Rezaei M; Ghavami R
SAR QSAR Environ Res; 2018 Jul; 29(7):551-565. PubMed ID: 30058412
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity.
Zhao R; Leung E; Grüner S; Schapira M; Houry WA
PLoS One; 2010 Apr; 5(4):e9934. PubMed ID: 20376192
[TBL] [Abstract][Full Text] [Related]
38. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.
Li Y; Zhang T; Schwartz SJ; Sun D
Drug Resist Updat; 2009; 12(1-2):17-27. PubMed ID: 19179103
[TBL] [Abstract][Full Text] [Related]
39. A chemical-biological study reveals C9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors.
Dal Piaz F; Vassallo A; Temraz A; Cotugno R; Belisario MA; Bifulco G; Chini MG; Pisano C; De Tommasi N; Braca A
J Med Chem; 2013 Feb; 56(4):1583-95. PubMed ID: 23362862
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
